Oral hypoglycemic agents in pregnancy: An update

Journal of Obstetrics and Gynecology of India

Volumn 63, Issue 2, 2013, Pages 82-87

  Kavitha, Nagandla ^a   De, Somsubhra ^a   Kanagasabai, Sachchithanantham ^a  

^a MELAKA MANIPAL MEDICAL COLLEGE   (India)

Author keywords

Gestational diabetes mellitus; Oral hypoglycemic agents; Type 2 diabetes

Indexed keywords

ACARBOSE; ACETOHEXAMIDE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA; TOLAZAMIDE; TOLBUTAMIDE; TROGLITAZONE;

BIRTH INJURY; CLINICAL PRACTICE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; GLOMERULUS FILTRATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN TREATMENT; LIVER TOXICITY; MACROSOMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; PREGNANCY DISORDER; PREMATURE LABOR; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; REVIEW; SIDE EFFECT; SYRINGE; WEIGHT GAIN;

EID: 84879504623     PISSN: 09719202     EISSN: 09756434     Source Type: Journal    
DOI: 10.1007/s13224-012-0312-z     Document Type: Review

References (61)

1. Jovanovic L, Pettitt DJ. Gestational diabetes mellitus. JAMA. 2001;286(20):2516-8.
2. Sheffield JS, Butler-Koster EL, Casey BM, et al. Maternal diabetes mellitus and infant malformations. Obstet Gynecol. 2002;100(5 pt 1):925-30.
3. Ferrara A, Kahn H, Quesenberry CP, et al. An increase in the incidence of gestational diabetes mellitus: Northern California. Obstet Gynecol. 2004;103:526-33.
4. Beischer NA, Oats J, Henry OA, et al. Incidence and severity of gestational diabetes mellitus according to country of birth in women living in Australia. Diabetes Care. 1991;40(Suppl. 2):35-8.
5. Langer O. Management of gestational diabetes. Clin Obstet Gynecol. 2000;43:106-15.
6. Schaefer-Graf UM, Buchanan TA, Xiang A, et al. Patterns of congenital anomalies and relationship to initial maternal fasting glucose levels in pregnancies complicated by type 2 and gestational diabetes. Am J Obstet Gynecol. 2000;182:313-20.
7. The HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358(19):1991-2002.
8. Lawlor DA, Lichtenstein P, Långström N. Association of maternal diabetes mellitus in pregnancy with offspring adiposity into early adulthood: sibling study in a prospective cohort of 280,866 men from 248,293 families. Circulation. 2011;123:258-65.
9. American College of Obstetricians and Gynecologists. Clinical management guidelines for obstetrician-gynecologists. ACOG Practice Bulletin. No 30. Obstet Gynecol. 2001;98:525-38.
10. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care. 2009;32(Suppl 1):S13-39.
11. Reece EA, Homko C, Miodovnik M, et al. A consensus report of the diabetes in pregnancy study group of North America Conference, Little Rock, Arkansas, May 2002. J Matern Fetal Neonatal Med. 2002;12:362-4.
12. Langer O. Maternal glycemic criteria for insulin therapy in gestational diabetes mellitus. Diabetes Care. 1998;21(suppl 2):B91-8.
13. Garcia-Bournissen F, Feig D, Koren G. Maternal-fetal transport of hypoglycaemic drug. Clin Pharmacokinet. 2003;42(4):303-13.
14. Sutherland H, Bewsher P, Cormack J, et al. Effect of moderate dosage of chlorpropamide in pregnancy on fetal outcome. Arch Dis Child. 1974;49(4):283-91.
15. Langer O, Conway DL, Berkus MD, et al. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med. 2000;343(16):1134-8.
16. Groop L, Luzi L, Melander A,et al. Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects. Diabetes. 1987;36(11):1320-8.
17. Groop LC, Barzilai N, Ratheiser K, et al. Dose-dependent effects of glyburide on insulin secretion and glucose uptake in humans. Diabetes Care. 1991;14(8):724-7.
18. Simonson DC, Farrannini E, Bevilacqua S, et al. Mechanism of improvement of glucose metabolism after chronic glyburide therapy. Diabetes Care. 1984;33:828-45.
19. Kemball ML, McIver C, Milner RD, et al. Neonatal hypoglycaemia in infants of diabetic mothers given sulphonylurea drugs in pregnancy. Arch Dis Child. 1970;45:696-701.
20. Elliot B, Langer O, Schenker S, et al. Insignificant transfer of glyburide occurs across the human placenta. Am J Obstet Gynecol. 1991;165:807-12.
21. Elliot B, Schenker S, Langer O, et al. Comparative placental transport of oral hypoglycemic agents. A model of human placental drug transfer. Am J Obstet Gynecol. 1994;171:653-60.
22. Elliot B, Langer O, Schussling F. A model of human placental drug transfer. Am J Obstet Gynecol. 1997;176:527-30.
23. Koren G. Glyburide and fetal safety: transplacental pharmacokinetic considerations. Reprod Toxicol. 2001;15:225-9.
24. Kraemer J, Klein J, Lubetsky A, et al. Perfusion studies of glyburide transfer across the human placenta: Implications for fetal safety. Am J Obstet Gynecol. 2006;195:270-4.
25. Langer O, editor. The diabetes in pregnancy dilemma: leading changes with simple solutions. New York: University Press of America; 2006.
26. Bailey CJ, Day C. Antidiabetic drugs. Br J Cardiol. 2003;10:128-13628.
27. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131(4):281-303.
28. Langer O. Oral anti-hyperglycemic agents for the management of gestational diabetes mellitus. Obstet Gynecol Clin North Am. 2007;34(2):255-74.
29. Bailey C. Metformin - an update. Gen Pharmacol. 1993;24:1299-309.
30. Sirtori CR, Pasik C. Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharmacol Res. 1994;30:187-228.
31. Langer O. When diet fails: insulin and oral hypoglycemic agents as alternatives for the management of gestational diabetes mellitus. J Matern Fetal Neonatal Med. 2002;11:218-25.
32. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002;137(1):25-33.
33. Hale TW, Kristensen JH, Hackett LP, et al. Transfer of metformin into human milk. Diabetologia. 2002;45(11):1509-14.
34. Gardiner SJ, Kirkpatrick CM, Begg EJ, et al. Transfer of metformin into human milk. Clin Pharmacol Ther. 2003;73(1):71-7.
35. Sevillano J, López-Pérez IC, Herrera E, et al. Englitazone administration to late pregnant rats produces delayed body growth and insulin resistance on their fetuses and neonates. Biochem J. 2005;389(3):913-8.
36. Chan LY, Yeung JH, Lau TK. Placental transfer of rosiglitazone in the first trimester of human pregnancy. Fertil Steril. 2005;83(4):955-8.
37. Stumvoll M. Thiazolidinedines - some recent development. Expert Opin Investig Drugs. 2003;12:1179-87.
38. Krentz AJ, Bailey CJ, Melander A. Thiazolidinediones for type 2 diabetes. BMJ. 2000;321:252-3.
39. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high risk Hispanic women. Diabetes. 2002;51:2796-803.
40. Cataldo NA, Abbasi F, McLaughlin TL, et al. Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone. Fertil Steril. 2001;76:1057-9.
41. Lebovitz HE. Alpha-glucosidase inhibitors. Source Department of Endocrinology, Metabolism, and Diabetes, State University of New York, Health Science Center at Brooklyn, New York, USA. Endocrinol Metab Clin North Am. 1997;26(3):539-551.
42. Bertini AM, Silva JC, Taborda W, et al. Perinatal outcomes and the use of oral hypoglycemic agents. J Perinat Med. 2005;33:519.
43. Anjalakshi C, Balaji V, Balaji MS, et al. A prospective study comparing insulin and glibenclamide in gestational diabetes mellitus in Asian Indian women. Diabetes Res Clin Pract. 2007;76:474-5.
44. Nicholson W, Baptiste-Roberts K. Oral hypoglycaemic agents during pregnancy: the evidence for effectiveness and safety. Best Pract Res Clin Obstet Gynaecol. 2011;25:51-63.
45. Kremer CJ, Duff P. Glyburide for the treatment of gestational diabetes. Am J Obstet Gynecol. 2004;190(5):1438-9.
46. Ogunyemi D, Jesse M, Davidson M. Comparison of glyburide versus insulin in management of gestational diabetes mellitus. Endocr Pract. 2007;13:427-8.
47. Kahn BF, Davies JK, Lynch AM, et al. Predictors of glyburide failure in the treatment of gestational diabetes. Obstet Gynecol. 2006;107(6):1303-9.
48. Bertini AM, Silva J, Taborda W, et al. Perinatal outcomes and the use of oral hypoglycemic agents. J Perinat Med. 2005;33(15):519-23.
49. Zarate A, Ochoa R, Hernandz M, et al. Effectiveness of acarbose in the control of glucose tolerance worsening in pregnancy. Ginecol Obstet Mex. 2000;68:42-5.
50. Rowan JA, Hague WM, Gao W, et al. MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358(19):2003-15.
51. Rowan JA, Rush EC, Obolonkin V, et al. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU). Body composition at 2 years of age. Diabetes Care. 2011;34(10):2279-84.
52. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, et al. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87:524-9.
53. Glueck CJ, Phillips H, Cameron D, et al. Continuing metformin throughout pregnancy in women with polycystic ovarian syndrome appears to safely reduce first trimester spontaneous abortions: a pilot study. Fertil Steril. 2001;75:46-52.
54. Glueck CJ, Wang P, Goldenberg N, et al. Pregnancy outcomes among women with polycystic ovarian syndrome treated with metformin. Hum Reprod. 2002;17:2858-64.
55. Glueck CJ, Ping W, Suichi K, et al. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovarian syndrome. Fertil Steril. 2002;77:520-5.
56. Coetzee EJ, Ekpebach C, Levitt NS. Combined use of metformin and glibenclamide in gestational and type 2 diabetics. Program and abstract presented at the 4th International Symposium on Diabetes and Pregnancy, 29-31 March 2007 at the Hilton Istanbul hotel, Istanbul, Turkey.
57. Hale TW, Kristensen JH, Hackett LP, et al. Transfer of metformin into human milk. Diabetologia. 2002;45:1509-14.
58. Akincia B, Tosunb P, Bekcib E, et al. Management of gestational diabetes by physicians in Turkey. Prim Care Diabetes. 2010;4:173-80.
59. Arbit E, Kidron M. Oral insulin: the rationale for this approach and current developments. J Diabetes Sci Technol. 2009;3(3):562-7.
60. Iyer H, Khedkar AP, Suryanarayan S, et al. An open label, two period, placebo controlled, multiple dose study to evaluate the effect of food on pharmacokinetic and pharmacodynamic of IN-105 10 mg in type 2 diabetes mellitus patients. Rome: European Association Study of Diabetes; 2008.
61. Kidron M, Dinh S, Menachem Y, Abbas R, Variano B, Goldberg M, Arbit E, Bar-On H. A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects. Diabet Med. 2004;21(4):354-7.